JP2009515927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515927A5 JP2009515927A5 JP2008540580A JP2008540580A JP2009515927A5 JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5 JP 2008540580 A JP2008540580 A JP 2008540580A JP 2008540580 A JP2008540580 A JP 2008540580A JP 2009515927 A5 JP2009515927 A5 JP 2009515927A5
- Authority
- JP
- Japan
- Prior art keywords
- asymptomatic
- latent
- heart failure
- use according
- pde iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010007554 Cardiac failure Diseases 0.000 claims 7
- 206010019280 Heart failure Diseases 0.000 claims 7
- 239000011575 calcium Substances 0.000 claims 7
- 230000002708 enhancing Effects 0.000 claims 6
- 230000035945 sensitivity Effects 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 5
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 3
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N Amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 229960000972 Enoximone Drugs 0.000 claims 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N Enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N Levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N Milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 229960002105 amrinone Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229960000692 levosimendan Drugs 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 1
- 229960003574 milrinone Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960002164 pimobendan Drugs 0.000 claims 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical group C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
- 231100000489 sensitizer Toxicity 0.000 claims 1
Claims (9)
- 無症候性（潜在性）心不全の患者の心臓サイズを減少させる薬物の調製のための又は無症候性（潜在性）心不全の患者における臨床症状の発現時期を延長する薬物の調製のためのホスホジエステラーゼIII(PDE III)阻害剤、Ca2+感受性増強薬又は薬剤的に許容可能なその誘導体の使用。
- 無症候性（潜在性）心不全が無症候性（潜在性）DCMである請求項１記載の使用。
- PDE III阻害剤がさらにカルシウム感受性増強作用を有する請求項１及び２記載の使用。
- PDE III阻害剤又はCa2+感受性増強薬がピモベンダン、ミルリノン、レボシメンダン、アムリノン、エノキシモン及びピロキシモン又は薬剤的に許容可能なその誘導体からなる群から選択される請求項１-３記載の使用。
- PDE III阻害剤又はCa2+感受性増強薬が経口又は非経口の剤形で利用される請求項１-４いずれか一項記載の使用。
- PDE III阻害剤又はCa2+感受性増強薬の１日あたりの投与量が１０μg/kgから１０mg/kgである、請求項１-５いずれか一項記載の使用。
- 前記患者がヒトを含む霊長類、犬、猫及び馬からなる群から選択された哺乳類である、請求項１-６いずれか一項記載の使用。
- 有効量のPDE III阻害剤又はCa 2+ 感受性増強薬又は薬剤的に許容可能なその誘導体を含む、心不全に罹患している患者における心臓サイズを減少するための医薬組成物。
- 無症候性（潜在性）心不全を罹患している患者の心臓サイズの減少に効果的である組成物を含む包装材料を含む製品であって、前記包装材料が、組成物が無症候性（潜在性）心不全に罹患している患者の心臓サイズを減少させることができる又は無症候性（潜在性）心不全の患者における症状の発現時期を延長することができることを示すラベルを含み、前記組成物が少なくとも一つのホスホジエステラーゼIII(PDE III)阻害剤又はCa2+感受性増強薬又は薬剤的に許容可能なその誘導体であるものを含む、上記製品。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05110689 | 2005-11-14 | ||
| EP05110689.6 | 2005-11-14 | ||
| PCT/EP2006/068231 WO2007054514A2 (en) | 2005-11-14 | 2006-11-08 | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515927A JP2009515927A (ja) | 2009-04-16 |
| JP2009515927A5 true JP2009515927A5 (ja) | 2010-01-07 |
| JP5312034B2 JP5312034B2 (ja) | 2013-10-09 |
Family
ID=37744668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540580A Active JP5312034B2 (ja) | 2005-11-14 | 2006-11-08 | 無症候性（潜在性）心不全の治療のためのｐｄｅｉｉｉ阻害剤の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070112010A1 (ja) |
| EP (2) | EP1951227B1 (ja) |
| JP (1) | JP5312034B2 (ja) |
| CN (2) | CN102784394A (ja) |
| AR (1) | AR056800A1 (ja) |
| AU (1) | AU2006310997B2 (ja) |
| CA (1) | CA2629367C (ja) |
| DK (1) | DK1951227T3 (ja) |
| ES (1) | ES2631879T3 (ja) |
| HU (1) | HUE033546T2 (ja) |
| PL (1) | PL1951227T3 (ja) |
| TW (1) | TW200735874A (ja) |
| WO (1) | WO2007054514A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| FI20040674A0 (fi) | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä tromboembolisten sairauksien estoon |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| WO2009137465A2 (en) * | 2008-05-05 | 2009-11-12 | University Of Rochester | Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
| US8664252B2 (en) * | 2008-11-25 | 2014-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
| NL1037569C2 (en) * | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| CA2915445C (en) | 2013-07-19 | 2024-04-23 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| PL3106150T3 (pl) | 2013-12-04 | 2022-01-03 | Boehringer Ingelheim Vetmedica Gmbh | Ulepszone kompozycje farmaceutyczne pimobendanu |
| US10537570B2 (en) * | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| EA039250B1 (ru) * | 2016-06-01 | 2021-12-23 | Бёрингер Ингельхайм Ветмедика Гмбх | Применение пимобендана для уменьшения размера сердца и замедления начала клинических симптомов у пациентов с асимптоматической сердечной недостаточностью вследствие митрального порока сердца |
| WO2022073954A1 (en) | 2020-10-08 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan in the anaesthesia of non-human mammals |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8101067A1 (es) | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona |
| GB8400863D0 (en) * | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
| PT83530B (pt) * | 1985-10-17 | 1989-05-31 | Smith Kline French Lab | Processo de preparacao de derivados da piridona, em especial derivados fenilicos |
| US4868182A (en) | 1986-11-05 | 1989-09-19 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
| DE3804490A1 (de) * | 1988-02-12 | 1989-08-24 | Heumann Pharma Gmbh & Co | Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB8824458D0 (en) | 1988-10-19 | 1988-11-23 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB8903130D0 (en) | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| WO2003012030A2 (en) | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
| EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
-
2006
- 2006-11-08 PL PL06829958T patent/PL1951227T3/pl unknown
- 2006-11-08 DK DK06829958.5T patent/DK1951227T3/en active
- 2006-11-08 WO PCT/EP2006/068231 patent/WO2007054514A2/en active Application Filing
- 2006-11-08 HU HUE06829958A patent/HUE033546T2/hu unknown
- 2006-11-08 CA CA2629367A patent/CA2629367C/en active Active
- 2006-11-08 JP JP2008540580A patent/JP5312034B2/ja active Active
- 2006-11-08 ES ES06829958.5T patent/ES2631879T3/es active Active
- 2006-11-08 CN CN201210144177XA patent/CN102784394A/zh active Pending
- 2006-11-08 AU AU2006310997A patent/AU2006310997B2/en active Active
- 2006-11-08 EP EP06829958.5A patent/EP1951227B1/en active Active
- 2006-11-08 EP EP17165100.3A patent/EP3210605A1/en not_active Withdrawn
- 2006-11-08 CN CNA2006800424125A patent/CN101309685A/zh active Pending
- 2006-11-10 AR ARP060104928A patent/AR056800A1/es not_active Application Discontinuation
- 2006-11-13 TW TW095141963A patent/TW200735874A/zh unknown
- 2006-11-14 US US11/559,467 patent/US20070112010A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/831,657 patent/US20100273807A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515927A5 (ja) | ||
| US9901568B2 (en) | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | |
| JP2022180461A5 (ja) | ||
| SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
| JP2010536849A5 (ja) | ||
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| JP2010518122A5 (ja) | ||
| JP2008543936A5 (ja) | ||
| JP2008524120A5 (ja) | ||
| JP2009537554A5 (ja) | ||
| JP2011522816A5 (ja) | ||
| JP2008516004A5 (ja) | ||
| JP2011502997A5 (ja) | ||
| JP2005508371A5 (ja) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NZ584686A (en) | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate | |
| JP2014521658A5 (ja) | ||
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
| JP2012021025A (ja) | メロキシカムを含む組成物 | |
| JP2008515980A5 (ja) | ||
| JP2010520246A5 (ja) | ||
| JP2014521641A5 (ja) | ||
| JP2018527305A5 (ja) | ||
| JP2015505295A5 (ja) | ||
| JP2006518731A5 (ja) |